Stockhub

Idogen AB: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

16 August 2022

  • curprev 08:4308:43, 16 August 2022 >Paris 785 bytes +785 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient's immune system from attacking biological agents, transplanted organs, and the body's own cells or tissues in Sweden. The company's advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII...."
Retrieved from "https://stockhub.co/research/Idogen_AB"